It comes a week after Chinese researchers filed an application to patent the drug to treat the new coronavirus, a bid that would give China sway over the global use of the therapy to fight the outbreak. Large areas of China have been paralyzed by the coronavirus epidemic, and Gilead’s drug is seen as a potential breakthrough after it showed signs of working on infected patients in the US. Chinese researchers are now testing the drug on 761 patients in clinical trials in Wuhan. The company also said that it is working with Chinese, US and World Health Organization officials to rapidly determine whether the drug can be used to treat the virus. BrightGene did not immediately respond to Bloomberg queries on its remdesivir production.

Source: The Edge Markets February 12, 2020 07:07 UTC